PTGX
Protagonist Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website rotagonist-inc.com
- Employees(FY) 111
- ISIN US74366E1029
Performance
1W
1M
3M
6M
YTD
1Y
Profile
Investment Analysis Report: PTGX
Overview
PTGX is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $1.62 billion. In this report, we will conduct a comprehensive analysis of PTGX's financial statements over the past three years to evaluate its financial he...
Technical Analysis of PTGX 2024-05-31
Overview:
In analyzing the technical indicators for PTGX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-03-02 07:24
- 2024-03-01 12:20
- 2024-03-01 12:00
- 2024-03-01 12:00
- 2024-03-01 09:55
- 2024-03-01 08:50
- 2024-03-01 05:36
Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
- 2024-02-29 23:20
- 2024-02-29 23:00
- 2024-02-29 23:00
- 2024-02-29 20:55
- 2024-02-29 19:50
- 2024-02-29 05:05
- 2024-02-27 16:38
Protagonist Therapeutics: Q4 Earnings Snapshot(Associated Press Finance)
- 2024-02-27 16:05
- 2024-02-27 03:05
- 2024-02-21 17:00
- 2024-02-21 04:00
- 2024-02-20 16:05
- 2024-02-20 03:05
- 2024-02-15 03:13
- 2024-02-07 17:00
- 2024-02-07 04:00
- 2024-02-02 13:03
- 2024-02-01 06:35
Takeda pays $300M to license Protagonist drug for blood disorder(BioPharma Dive)
- 2024-01-31 16:05
- 2024-01-31 03:05
- 2024-01-29 07:30
- 2024-01-12 09:02
- 2024-01-03 07:30